Notes Payable and Debt (Details Textual) (USD $)
 3 Months Ended 6 Months Ended 12 Months Ended 236 Months Ended 6 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Number_Of_Notes
Jun. 30, 2011
Dec. 31, 2011
Jun. 30, 2012
Jun. 30, 2012
RG [Member]
Jun. 30, 2012
ISVP [Member]
Dec. 31, 2011
ISVP [Member]
Dec. 31, 2011
Robert and Thomas Gipson [Member]
Dec. 27, 2011
Robert Gipson [Member]
Dec. 27, 2011
Thomas Gipson [Member]
Jun. 01, 2011
Arthur Koenig [Member]
Dec. 31, 2011
Ingalls Snyder LLC [Member]
Jun. 30, 2012
Molecular Imaging and Other Products [Member]
Jun. 30, 2012
Demand Notes Payable [Member]
Jun. 30, 2011
Demand Notes Payable [Member]
Jun. 30, 2012
Demand Notes Payable [Member]
Jun. 30, 2011
Demand Notes Payable [Member]
Notes Payable and Debt (Textual) [Abstract]                                      
Convertible notes payable $ 21,827,588   $ 21,827,588   $ 21,827,588 $ 21,827,588       $ 7,172,412         $ 1,000,000        
Future payments as a percentage of pre-commercial revenue                             2.00%        
Notes payables additional compensation as a percentage of future net sales per $1000000 outstanding principle                             0.50%        
Percentage of shares to be held by purchases considered to determine effective conversion under option 1               19.90%                      
Percentage of shares to be held by purchases considered to determine effective conversion under option 2               9.99%                      
Recorded Beneficial Conversion Feature             380,000 1,400,000                      
Percentage of outstanding common stock                 9.99%   50.10% 15.20% 7.00% 9.99%          
Demand notes payable value 6,185,000   6,185,000   5,900,000 6,185,000                          
Interest expenses Related to BCF 0 362,499 0 724,998                       105,287 100,078 208,225 186,224
Notes Payable and Debt (Additional Textual) [Abstract]                                      
Unsecured promissory note 1,000,000   1,000,000     1,000,000                          
Interest expenses 105,716 465,258 209,113 919,009 18,000 14,698,223                          
Additional Debt         $ 2,525,000                            
Unsecured convertible promissory notes conversion options     Conversion Policies (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii).                                
Unsecured convertible promissory notes conversion price per common stock share $ 2.50   $ 2.50     $ 2.50                          
Notes Payable, Description     Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under.                                
Number of unsecured promissory notes issued     2